/
As used herein, the terms Company, Cencora, we, us, or our refer to Cencora, Inc., a Delaware corporation. Cencora is one of the largest global pharmaceutical sourcing and distribution services companies, helping both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care.
Operating margin is thin at 0.82%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue grew 9.3%, steady but not accelerating.
ROIC dropped from 26.65% to 22.66%, capital efficiency is deteriorating.
Profitability & Returns
Revenue (TTM)
$328.68B
▲ +9.3% YoY
Net Income (TTM)
$2.55B
▲ +3.0% YoY
Op. Margin
0.85%
ROIC
15.73%
▼ -4.0pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$1.56B
▲ +7.0% YoY
Op. Cash Flow (TTM)
$2.28B
▲ +11.2% YoY
Net Debt
$10.21B
Cash & Equiv.
$2.18B
5Y CAGR: +11.1%
5Y CAGR: +11.8%
Continue Research